Immune-cell crosstalk in multiple sclerosis

Interactions between the B and T cells of the human immune system are implicated in the brain disease multiple sclerosis. It emerges that B cells make a protein that is also made in the brain, and that T cells recognize this protein.
Richard M. Ransohoff is at Third Rock Ventures, Boston, Massachusetts 02116, USA, and in the Department of Cell Biology, Harvard Medical School, Boston.

Search for this author in:

A hallmark of the disease multiple sclerosis is an inflammatory autoimmune attack1 on the proteins of the myelin sheath, a structure that wraps around the nerve fibres that project from neurons. The myelin sheath provides protection and nourishment to nerve fibres and enables efficient transmission of nerve impulses. Myelin-sheath injury causes a range of symptoms, depending on the neurons that are affected. Which immune-system cells and protein targets have key roles in the initiation and progression of multiple sclerosis is not fully understood, and such information might aid the development of new treatments. Writing in Cell, Jelcic et al.2 present an analysis of immune-system cells found in people with multiple sclerosis that deepens our understanding of how immune cells might contribute to this disease.

One factor linked3,4 to the risk of developing multiple sclerosis is the possession of a particular version of a protein called HLA. HLA proteins enable cells to display antigens — fragments of proteins — on their surfaces. If the receptor for an antigen (the T-cell receptor; TCR) on a T cell recognizes an antigen presented by an HLA protein, the T cell is activated to trigger an immune response against cells that express the antigen. Variations in the antigen-binding capacity of different HLA proteins and in the antigen-recognition capacity of TCRs enable the body to respond to a wide range of antigens associated with disease-causing microorganisms. However, there is a danger that if an HLA protein efficiently binds an antigen that is normally part of the body, and if a T cell that recognizes the HLA–antigen complex is activated, autoimmunity could develop. Such a mechanism might underlie the fact that the version of HLA called HLA-DR15 is a risk factor for multiple sclerosis3, and is estimated4 to contribute 60% of the total genetic risk for developing the condition.

T cells from people with multiple sclerosis are more prone to divide in vitro than are T cells from people without the condition3. Such cell division is reminiscent of the division that occurs as the result of normal immune-cell activation by an antigen stimulus, but in this case it does not seem to require the addition of an antigen stimulus to the sample of immune cells3. This suggests either that the normal requirement for antigen recognition is being bypassed, or that these T cells recognize an antigen that is present on other immune cells in the blood sample. Jelcic et al. investigated further, analysing in more detail the behaviour of immune cells in blood samples of people with multiple sclerosis. They convincingly demonstrate that both T cells and another type of immune cell called a B cell from these samples could proliferate when grown in vitro. The authors term this type of division autoproliferation, because it occurs spontaneously in vitro without the addition of an antigen.

Jelcic et al. found that signalling through a TCR-initiated T-cell proliferation, and that cell proliferation was associated with the production by T cells of a signalling protein called IFN-γ (Fig. 1), which is associated with multiple sclerosis5. IFN-γ is a potent activator of a category of immune cells called macrophages, which directly damage the myelin sheath6,7 in multiple sclerosis.

Figure 1 | Immune-cell action associated with multiple sclerosis. Jelcic et al.2 report that B cells of the immune system present in the bloodstream make a protein called RASGRP2. These cells use a protein called HLA to present a peptide fragment (an antigen) of RASGRP2 on their cell surface. If this antigen is recognized by the T-cell receptor (TCR) of another immune cell called a T cell, this interaction leads to the proliferation of both the T cells and the B cells, a phenomenon that the authors call autoproliferation. Their evidence indicates that these autoproliferating T cells can, by an unknown route, cross the blood–brain barrier to enter the brain. RASGRP2 is also found in brain tissue. If neurons or other brain cells express RASGRP2, this might trigger T cells that infiltrate the brain to orchestrate an autoimmune attack by producing inflammatory mediators. For example, the production of IFN-γ proteins by activated T cells could stimulate the macrophages of the immune system, which are known6,7 to attack the myelin-sheath structure that protects nerve fibres and supports neuronal function. This in turn could lead to the development of multiple sclerosis.

The authors implicate B-cell proliferation in driving T-cell autoproliferation, because neither T cells nor B cells divided if the cultured cells were exposed to a drug called ibrutinib. Ibrutinib inhibits the protein BTK, which is essential for signalling downstream of the B-cell antigen receptor that leads to B-cell proliferation8. Interestingly, a phase IIb clinical trial (see has reported preliminary evidence that the BTK inhibitor evobrutinib could potentially provide benefit for people with multiple sclerosis (see

Each of the multiple-sclerosis treatments currently in use suppresses disease-associated brain inflammation, but in different ways. Jelcic et al. took advantage of this to test whether interactions between B cells and T cells are needed for T-cell autoproliferation, and whether this phenomenon might be involved in processes that lead to the symptoms of multiple sclerosis.

The authors analysed blood samples from people with the disease who were receiving different anti-inflammatory treatments, and compared these results with control samples from people with the disease who were not receiving treatment. For those receiving an antibody called natalizumab, which causes an increase in the numbers of T cells and immature B cells in the blood, in vitro analysis showed that autoproliferation of B cells and T cells was increased compared with the controls. Samples from those receiving an antibody called rituximab, which depletes B cells from the bloodstream, had much-reduced T-cell proliferation compared with controls.

This analysis of the effect of anti-inflammatory treatments that affect T cells or B cells provides evidence consistent with the authors’ model that clinically relevant interactions between B cells and T cells occur in multiple sclerosis. For many years, it was generally thought that B cells do not have a role in multiple sclerosis, because of results from animal studies9. This view changed when striking benefits were observed in clinical trials of B-cell depletion for multiple-sclerosis treatment1012.

Jelcic and colleagues needed to answer the question of whether the autoproliferating T cells contribute to the development of multiple sclerosis. To address this tough problem, the authors analysed the cellular descendants of individual proliferating T cells from the blood of people with multiple sclerosis. They looked at the variable portions of the TCRs present in the cells because these variable regions provide a unique pattern, akin to a barcode, that can identify any T cell and its genetically identical descendants — which form a cellular lineage termed a clone.

In rigorous and challenging experiments using material from two people who had multiple sclerosis, the authors analysed T cells found in brain tissue taken at biopsy or post-mortem and compared these with T cells from the same person’s blood samples taken before brain-tissue samples were obtained. The authors found that T cells from blood samples that underwent autoproliferation in vitro belonged to an identical cellular lineage that matched T cells found in the brain-tissue samples taken from the same person.

This finding strongly suggests that some proliferating cells in the blood of people with multiple sclerosis could enter their brain. Once there, such T cells might release immune-signalling molecules called cytokines, such as macrophage-stimulating IFN-γ, that could initiate inflammatory tissue injury. Immune cells are always present in the cerebrospinal fluid that bathes the brain and spinal cord, and IFN-γ-producing T cells13,14 and proliferating T cells15 have previously been identified in the cerebrospinal fluid of individuals with multiple sclerosis. Jelcic and colleagues’ findings therefore highlight the significance of previous observations and provide additional support for established models of how this disease proceeds.

A final conundrum remains: what are the antigenic target(s) of these T cells? This is a key question because the relevant self-antigens driving multiple sclerosis have not been definitively identified. To try to answer this, the authors analysed a clonal cell population grown in vitro, derived from one T cell and its descendants that were present in the blood and the post-mortem brain of a person with multiple sclerosis. Jelic and colleagues used an innovative approach that relied on computational evaluation of data obtained using standard methods to stimulate T cells. The authors evaluated an almost unimaginably large number of structurally similar but non-identical peptides for their capacity to act as an antigen that would generate a response from this T-cell population. They uncovered an antigen from the protein RASGRP2 as one that probably stimulates the TCR of this T-cell population. RASGRP2 had not previously been linked to processes related to multiple sclerosis. The authors demonstrated that RASGRP2 is expressed both in B cells that elicit T-cell proliferation and in brain tissue.

Jelcic and colleagues’ study provides a model for how B-cell and T-cell interactions outside the brain might generate disease-contributing T cells that then enter the brain. Their discovery of an antigen associated with multiple sclerosis might, if other such antigens are identified in the future, reveal how autoimmunity occurs and, perhaps, how it could be remedied.

Nature 563, 194-195 (2018)

doi: 10.1038/d41586-018-07063-z
Nature Briefing

Sign up for the daily Nature Briefing email newsletter

Stay up to date with what matters in science and why, handpicked from Nature and other publications worldwide.

Sign Up


  1. 1.

    Wekerle, H. Acta Neurol. Scand. 136 (Suppl. 201), 22–25 (2017).

  2. 2.

    Jelcic, I. et al. Cell 175, 85–100 (2018).

  3. 3.

    Mohme, M. et al. Brain 136, 1783–1798 (2013).

  4. 4.

    Oksenberg, J. R., Baranzini, S. E., Sawcer, S. & Hauser, S. L. Nature Rev. Genet. 9, 516–526 (2008).

  5. 5.

    Panitch, H. S., Hirsch, R. L., Haley, A. S. & Johnson, K. P. Lancet 329, 893–895 (1987).

  6. 6.

    Bitsch, A., Schuchardt, J., Bunkowski, S., Kuhlmann, T. & Bruck, W. Brain 123, 1174–1183 (2000).

  7. 7.

    Bruck, W. et al. Immunobiology 195, 588–600 (1996).

  8. 8.

    Hendriks, R. W., Yuvaraj, S. & Kil, L. P. Nature Rev. Cancer 14, 219–232 (2014).

  9. 9.

    Mertin, J. Proc. R. Soc. Med. 70, 871–874 (1977).

  10. 10.

    Greenfield, A. L. & Hauser, S. L. Annls Neurol. 83, 13–26 (2018).

  11. 11.

    Hauser, S. L. et al. N. Engl. J. Med. 358, 676–688 (2008).

  12. 12.

    Wekerle, H. Autoimmunity 50, 57–60 (2017).

  13. 13.

    Kivisäkk, P. et al. Clin. Exp. Immunol. 129, 510–518 (2002).

  14. 14.

    Restorick, S. M. et al. Brain Behav. Immun. 64, 71–79 (2017).

  15. 15.

    Richert, J. R., McFarlin, D. E., Rose, J. W., McFarland, H. F., Greenstein, J. I. J. Neuroimmunol. 5, 317–324 (1983).

Download references

Competing Financial Interests

R. M. R. was employed by Biogen, the manufacturer of natalizumab, from October 2014 to November 2017. He retains a small equity interest in Biogen.